Patents by Inventor Bryan Perry

Bryan Perry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240098473
    Abstract: Disclosed herein are methods, systems and GUIs for providing situational awareness about emergency incidents to emergency service providers (ESPs), for example, between different Public Safety Answering Points. In particular, the use of data indicators, notifications and banners can be used to provide a GUI rich in situational awareness for efficient emergency response.
    Type: Application
    Filed: September 21, 2023
    Publication date: March 21, 2024
    Inventors: Emily INGRAM, Gabriel Charles MAHONEY, David Paul SEHNERT, John Robert KATT, Karin Janeen MARQUEZ, BingJun Perry SY, Bryan Wright KELLER, Andrew Lee HWANG
  • Patent number: 11912409
    Abstract: An unmanned aerial vehicle may include a fuselage and an anchor structure coupled to the fuselage and including a wing retention structure and a power module retention structure. The unmanned aerial vehicle may also include a wing releasably coupled to the wing retention structure, thereby coupling the wing to the fuselage, and a power module releasably coupled to the power module retention structure, thereby coupling the power module to the fuselage.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: February 27, 2024
    Assignee: Zipline International Inc.
    Inventors: Paul Perry, Zoltan Laszlo, Scott Parker, Nathan Goldsberry, Bryan Wade, Keenan Wyrobek, Brian Boomgaard, Zhefei Li, Sven Blaser
  • Patent number: 10987377
    Abstract: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: April 27, 2021
    Assignee: Advanced Inhalation Therapies (AIT), Ltd.
    Inventors: Bruce R. Murray, Christopher C. Miller, Douglas R. Hole, Bryan Perry
  • Publication number: 20180250329
    Abstract: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
    Type: Application
    Filed: January 31, 2018
    Publication date: September 6, 2018
    Inventors: Bruce R. Murray, Christopher C. Miller, Douglas R. Hole, Bryan Perry
  • Patent number: 8518457
    Abstract: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: August 27, 2013
    Assignee: Pulmonox Technologies Corporation
    Inventors: Christopher C. Miller, Douglas R. Hole, Bruce R Murray, Bryan Perry
  • Patent number: 8262270
    Abstract: A system and method for providing added functionality to a personal transporter by way of adding increased lighting, sound, and cargo carrying options is described. The system can include front, side, and rear lighting and an audio alert system. The system can further include flatbed structures for carrying hazardous or other materials, as well as cargo organizing systems for carrying supplies and equipment.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: September 11, 2012
    Assignee: Consultus, LLC
    Inventors: David Purinton, Alex Purinton, Shayne Ashton, Gary Sivertsen, Mary Sivertsen, Bryan Perry
  • Publication number: 20070104653
    Abstract: Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.
    Type: Application
    Filed: November 10, 2006
    Publication date: May 10, 2007
    Inventors: Christopher Miller, Douglas Hole, Bruce Murray, Bryan Perry
  • Patent number: 7023354
    Abstract: An automated warning system for a platform assembly. The system includes a measuring device mountable on the platform assembly for measuring a parameter representing loading on the assembly, a warning device for generating a warning, and a processor operatively connected to the measuring device and the warning device. The processor is configured to receive information relating to at least one of the design and operation of at least one of the platform assembly and the object, determine a limit for the parameter based on the information, compare the parameter to the limit, and activate the warning device to generate a warning when the parameter compares unfavorably to the limit.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: April 4, 2006
    Assignee: The Boeing Company
    Inventors: William Bryan Perry, David Earl Headley
  • Patent number: 6920876
    Abstract: The present invention is directed to a nitric gas dispenser for mammals on the run. The dispenser has a housing that contains a valve mechanism. The valve mechanism is interconnected between a nitric gas dispersal component that provides nitric gas at a desired pressure and a gas delivery system that provides the nitric gas at the desired pressure to the mammal. The valve mechanism controls the flow of the nitric gas between the nitric gas dispersal component and the gas delivery system. The dispenser also has a pressure sensor that is positioned along the gas delivery system and determines when the mammal is taking a breadth. If the pressure sensor determines the mammal is taking a breadth, the pressure sensor transmits a breadth signal to a microprocessor. The microprocessor then determines if the mammal is within a prescribed time frame for the mammal to be administered nitric gas.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: July 26, 2005
    Assignee: Pulmonox Technologies Corporation
    Inventors: Christopher Miller, Bryan Perry, Robert E. Lee, Stephen H. Fairbanks
  • Publication number: 20030150457
    Abstract: The present invention is directed to a nitric gas dispenser for mammals on the run. The dispenser has a housing that contains a valve mechanism. The valve mechanism is interconnected between a nitric gas dispersal component that provides nitric gas at a desired pressure and a gas delivery system that provides the nitric gas at the desired pressure to the mammal. The valve mechanism controls the flow of the nitric gas between the nitric gas dispersal component and the gas delivery system. The dispenser also has a pressure sensor that is positioned along the gas delivery system and determines when the mammal is taking a breadth. If the pressure sensor determines the mammal is taking a breadth, the pressure sensor transmits a breadth signal to a microprocessor. The microprocessor then determines if the mammal is within a prescribed time frame for the mammal to be administered nitric gas.
    Type: Application
    Filed: December 10, 2002
    Publication date: August 14, 2003
    Inventors: Christopher Miller, Bryan Perry, Robert E. Lee, Stephen H. Fairbanks
  • Publication number: 20030070674
    Abstract: The administration of aerosolized nitric oxide donors or type V phosphodiesterase inhibitor in controlled doses to horses during high intensity exercise is described. Aerosolized nitric oxide donors (in conjunction with intravenous type V phosphodiesterase inhibitor) and type V phosphodiesterase inhibitor are beneficial to prevent exercise induced pulmonary hemorrhage by reducing transmural pulmonary artery pressure with a concomitant decrease in pulmonary capillary stress failure. The administration of aerosolized nitric oxide donors and type V phosphodiesterase inhibitors is viewed as a novel therapeutic modality in the alleviation of capillary stress failure and EIPH in performance horses.
    Type: Application
    Filed: October 14, 2002
    Publication date: April 17, 2003
    Inventors: Bryan Perry, Christopher Miller, Douglas Hole